TCGA-A8-A0A6-01A-12R-A056-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 21
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.530
- PROTEIN_SECRETION+0.470
- INTERFERON_GAMMA_RESPONSE+0.420
- KRAS_SIGNALING_UP+0.420
- IL6_JAK_STAT3_SIGNALING+0.380
- INTERFERON_ALPHA_RESPONSE+0.370
- COMPLEMENT+0.350
- PANCREAS_BETA_CELLS+0.330
- INFLAMMATORY_RESPONSE+0.320
- ANGIOGENESIS+0.220
Top 10 suppressed
- MYC_TARGETS_V2-0.660
- E2F_TARGETS-0.590
- G2M_CHECKPOINT-0.530
- MYC_TARGETS_V1-0.380
- DNA_REPAIR-0.370
- ESTROGEN_RESPONSE_EARLY-0.340
- WNT_BETA_CATENIN_SIGNALING-0.330
- MITOTIC_SPINDLE-0.290
- OXIDATIVE_PHOSPHORYLATION-0.290
- APICAL_SURFACE-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518324 | — | D | 0.888 |
| 2 | SRR8518300 | — | A | 0.875 |
| 3 | SRR8518332 | — | D | 0.858 |
| 4 | SRR8518195 | — | A | 0.857 |
| 5 | 88340 | EPN | Supratentorial EPN | 0.855 |
| 6 | 2d12ea90-c4f4-4aca-b353-360057b446e2 | — | — | 0.840 |
| 7 | f26d1599-6e75-4c0d-8b40-c7e45fe9da76 | — | — | 0.835 |
| 8 | TCGA-97-A4LX-01A-11R-A24X-07 | — | cohortA1 | 0.834 |
| 9 | SAMN03290950 | — | — | 0.829 |
| 10 | DRR168557 | — | — | 0.829 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.530 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.470 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.420 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.420 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.380 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.370 | Inavolisib | — uncovered |
| COMPLEMENT | 0.350 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.330 | Cobimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.320 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.220 | Remibrutinib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.190 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.150 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.140 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.090 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.090 | Inavolisib | — uncovered |
| APOPTOSIS | 0.070 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.070 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.050 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.050 | Remibrutinib | — uncovered |